Compare PCT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCT | CNTA |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United Kingdom |
| Employees | 174 | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 6.1B |
| IPO Year | N/A | 2021 |
| Metric | PCT | CNTA |
|---|---|---|
| Price | $12.89 | $39.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $13.00 | ★ $43.17 |
| AVG Volume (30 Days) | ★ 4.9M | 1.1M |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $380.44 | N/A |
| Revenue Next Year | $203.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.93 | $10.95 |
| 52 Week High | $17.37 | $40.26 |
| Indicator | PCT | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 75.32 | 70.34 |
| Support Level | $12.81 | $39.36 |
| Resistance Level | $13.29 | $39.86 |
| Average True Range (ATR) | 0.85 | 0.09 |
| MACD | 0.08 | -0.19 |
| Stochastic Oscillator | 90.02 | 68.75 |
PureCycle Technologies Inc is a Florida-based corporation focused on commercializing a patented dissolution process to physically separate the polymer from other plastics, color, and contaminants (the Technology), originally developed by The Procter & Gamble Company (P&G), for restoring waste polypropylene into resin with near-virgin characteristics, called PureFive resin. PureFive resin represents the family of recycled resin products produced, including ultra-pure resin and other grades used for compounding to meet customer specifications, which has similar properties and applicability for reuse as virgin polypropylene. It has a single operating segment, which encompasses integrated business activities related to the recycling of polypropylene into resins.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.